06:24 AM EDT, 08/21/2025 (MT Newswires) -- Nordson's ( NDSN ) shares climbed early Thursday after the precision technology company reported fiscal third-quarter results above market estimates, buoyed by double-digit revenue growth in two of its main segments.

Adjusted earnings came in at $2.73 a share for the quarter ended July, up from $2.41 the year before, the company said late Wednesday. The consensus on FactSet was for non-GAAP EPS of $2.64. Sales improved 12% to $741.5 million, topping the Street's view for $723.6 million. The stock jumped 5.4% in the most recent premarket activity.

"The Nordson ( NDSN ) team responded effectively to dynamic demand conditions in key end markets and delivered on its promises, realizing solid year-over-year organic growth in the quarter," Chief Executive Sundaram Nagarajan said in a statement. "Operational excellence drove strong profit performance, increasing adjusted earnings per share by 13% and (earnings before interest, taxes, depreciation and amortization) by 15%."

Sales in the medical and fluid solutions business advanced 32% to $219.5 million, while advanced technology solutions inclined 17% to $171.3 million. Revenue in the industrial precision solutions segment edged up 0.5% to $350.8 million, including a 2% decrease in organic sales due to weaker systems demand in polymer processing, which offset growth in most other product lines, according to the company.

Revenue rose across all geographies the firm operates in, led by a 23% gain in the Asia-Pacific region. Selling and administrative expenses widened to $206.5 million from about $201.9 million in the prior-year quarter.

For fiscal 2025, Nordson ( NDSN ) said its adjusted EPS are now tracking "slightly above" the midpoint of its original outlook, while sales are seen "slightly below" the midpoint. In December, the company provided a full-year adjusted EPS guidance range of $9.70 to $10.50 and sales of between $2.75 billion and $2.87 billion. The Street is looking for non-GAAP EPS of $10.05 and sales of $2.79 billion.

"Following a strong third quarter, I am pleased that we are able to affirm our full-year sales guidance and earnings expectations," Nagarajan said.

The backlog is down roughly 5% on a sequential basis following the third quarter, prompting the company to believe it will meet its fiscal 2025 outlook based on completing the planned sale of its medical contract manufacturing business in the ongoing three-month period, it said. In May, Nordson ( NDSN ) agreed to sell its design and development contract manufacturing businesses in Ireland and Mexico to Quasar Medical.